


**Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow Fever vaccination**

Ismael Artur da Costa-Rocha<sup>a\*</sup>, Ketty Lysie Libardi Lira Machado<sup>b\*</sup>, Ana Carolina Campi-Azevedo<sup>a</sup>, Andréa Teixeira-Carvalho<sup>a</sup>, Vanessa Peruhype-Magalhães<sup>a</sup>, Sheila Maria Barbosa de Lima<sup>c</sup>, Emily Hime Miranda<sup>c</sup>, Gisela Freitas Trindade<sup>c</sup>, Thays Zanon Casagrande<sup>b</sup>, Samira Tatiyama Miyamoto<sup>b</sup>, Sávio Carvalho Deotti<sup>b</sup>, Rafaela Villa Real Barbosa<sup>b</sup>, Priscila Costa Martins Rocha<sup>b</sup>, Erica Vieira Serrano<sup>b</sup>, Valquiria Garcia Dinis<sup>b,d</sup>, Sônia Alves Gouvêa<sup>b</sup>, Maria Bernadete Renoldi de Oliveira Gavi<sup>b</sup>, Lidia Balarini da Silva<sup>b</sup>, Ruben Horst Duque<sup>b</sup>, Ana Paula Espíndula Gianordoli<sup>b</sup>, Maria de Fatima Bissoli<sup>b</sup>, Maria da Penha Gomes Gouvea<sup>b</sup>, Lauro Ferreira da Silva Pinto-Neto<sup>d</sup>, Ana Paula Neves Burian<sup>e</sup>, Francieli Fontana Sutile Tardetti Fantinato<sup>f</sup>, Gecilmara Salviato Pileggi<sup>g</sup>, Licia Maria Henrique da Mota<sup>h</sup>, Valéria Valim<sup>b#</sup> and Olindo Assis Martins-Filho<sup>a#</sup>

Heatmap Timeline Kinetic Profiles of Serum Biomarkers After 17DD-YF Primary Vaccination  
According to the Type of Autoimmune Disease



Supplementary Figure 1 - Heatmap Timeline Kinetic Profiles of Serum Biomarkers After 17DD-YF Primary Vaccination According to the Type of Autoimmune Disease. Heatmaps were constructed considering the baseline fold change values at each time point along the kinetic follow-up (D3-4, D5-6, D7 and D14-28). This approach was employed to draw the overall change in the serum biomarkers profile after primary 17DD-YF vaccination of Autoimmune Disease patients segregated according to the type of autoimmune disease [Rheumatoid Arthritis (RA, n=38), Spondyloarthritis (SpA, n=51), Systemic Lupus Erythematosus (SLE, n=21) and Sjögren's Syndrome (SS, n=30)]. Data interpretation was carried out based on the color keys were employed underscore the baseline fold value = 1.0 as the reference for unaltered levels (■), the baseline fold value <1.0 for decreased levels (■) and the baseline fold value >1.0 for increased levels (■), according to the paired sample collected at D0.